P-glycoprotein expression in osteosarcoma: A basis for risk-adapted adjuvant chemotherapy

Journal of Orthopaedic Research

Volumn 17, Issue 5, 1999, Pages 629-632

  Baldini, N ^a   Scotlandi, K ^a   Serra, M ^a   Picci, P ^a   Bacci, G ^a   Sottili, S ^a   Campanacci, M ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CELLS; CHEMOTHERAPY; DIAGNOSIS; ONCOLOGY; PROTEINS;

GLYCOPROTEINS; OSTEOSARCOMA;

BONE;

CISPLATIN; DOXORUBICIN; ETOPOSIDE; FOLINIC ACID; GLYCOPROTEIN P; IFOSFAMIDE; METHOTREXATE;

ADOLESCENT; ADULT; ARTICLE; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; OSTEOSARCOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TREATMENT OUTCOME;

EID: 0033197875     PISSN: 07360266     EISSN: None     Source Type: Journal    
DOI: 10.1002/jor.1100170502     Document Type: Article

References (13)

1. 1 Bacci G, Picci P, Ferrari S, Ruggieri P, Casadei R, Tienghi A, Brach del prever A, Gherlinzoni F, Mercuri M, Monti G: Primary chemotherapy and delayed surgery for nonmetastatic osteosarcoma of the extremities: results in 164 patients pre‐operatively treated with high doses of methotrexate followed by cisplatin and doxorubicin. Cancer 72: 3227–3238, 1993
2. 2 Baldini N, Scotlandi K, Barbanti‐Brodano G, Manara MC, Maurici D, Bacci G, Bertoni F, Picci P, Sottili S, Campanacci M, Serra M: Expression of P‐glycoprotein in high‐grade osteosarcomas in relation to clinical outcome. N Engl J Med 333: 1380–1385, 1995
3. 3 Blaney SM, Smith MA, Grem JL: Doxorubicin: role in the treatment of osteosarcoma. In: Osteosarcoma in Adolescents and Young Adults: New Developments and Controversies, pp 55–73. Ed by G Bennett humphrey. Boston, Kluwer Academic Publishers. 1993
4. 4 Bramwell VH: The role of chemotherapy in the management of non‐metastatic operable extremity osteosarcoma. Semin Oncol 24: 561–571, 1997
5. 5 Bruland ØS, Pihl A: On the current management of osteosarcoma: a critical evaluation and a proposal for a modified treatment strategy. Eur J Cancer 11: 1725–1731, 1997
6. 6 Campanacci M, Bacci G, Bertoni F, Picci P, Minutillo A, Franceschi C: The treatment of osteosarcoma of the extremities: twenty year's experience at the Istituto Ortopedico Rizzoli. Cancer 48: 1569–1581, 1981
7. 7 Chan HS, Grogan TM, Haddad G, Deboer G, Ling V: P‐glycoprotein expression: critical determinant in the response to osteosarcoma chemotherapy. J Natl Cancer Inst 89: 1706–1715, 1997
8. 8 Dahlin DC, Unni KK: Osteosarcoma of bone and its important recognizable varieties. Am J Surg Pathol 1: 61–72, 1977
9. 9 Fisher GA, Sikic BI: Clinical studies with modulators of multi‐drug resistance. Hematol Oncol Clin North Am 9: 363–382, 1995
10. 10 Kaye SB: P glycoprotein (P‐gp) and drug resistance: time for reappraisal? Br J Cancer 67: 641–643, 1993
11. 11 Pinedo HM, Giaccone G: P‐glycoprotein: a marker of cancer‐cell behavior. N Engl J Med 333: 1417–1419, 1995
12. 12 Scotlandi K, Serra M, Nicoletti, G, Vaccari M, Manara MC, Nini G, Landuzzi L, Colacci A, Bacci G, Bertoni F, Picci P, Campanacci M, Baldini N: Multidrug resistance and malignancy in human osteosarcoma. Cancer Res 56: 2434–2439, 1996
13. 13 Souhami RL, Craft AW, Van der Eijken JW, Nooij M, Spooner D, Bramwell VH, Wierzbicki R, Malcom AJ, Kirkpatrick A, Uscinska BM, Van Glabbeke M, Machin D: Randomised trial of two regimens of chemotherapy in operable osteosarcoma: a study of the European Osteosarcoma Intergroup. Lancet 350: 911–917, 1997